Great to hear from you DJ,
Yes, one step at a time, the right step at the right time is certainly the wisest, most methodical approach. Amongst other things ,no doubt Tony has been prioritised his energy into completing the FDA pathway, rather than talking business with potential Telehealth clients.
Tony can prefer a lot of things. But this doesn't mean that these discussions can't be evolving. I also understand that management aren't sitting on their hands while MH does their thing. Ultimately, exclusivity will only be achieved through a complete takeover.
Yes, we never like distractions, but the real world of business doesn't work that way. I hate it when I am focussed on a task and the phone rings. But I need to tend to these calls because they are my customers and they help me bring in the bacon. Ignoring those calls ensures I will have a few dead months without work.
So to me it is inconceivable that upon FDA approval, management decides to begin discussions with Telehealth companies.
Another thing- It was commented that this cannot be marketed prior to FDA approval.
Let me point out that sales agreements and marketing are not necessarily the same thing: the marketing the FDA is concerned about is not sales agreement between wholsaler and vendor; instead the prohibition concerns the sale/marketing of the product to the end consumer. Therefore a contract 'subject to FDA approval' can certainly be formed.
The spec sector has been walloped. Yet RAP has held up surprisingly well.
Of course I'd prefer to see it sitting beyond the 40 cent mark at the moment. I had some pretty optimistic targets and expectations of where this might be in regards to milestones and associated share prices.
Early last year it was hoped that FDA approval might have arrived early this year. Things don't always happen as quickly as we hope and wish, but, with good companies, they do eventually happen. If we had the MH trials commencements announced much earlier while the sp was say 10 cents, everyone would have been orgasmic over this stock. Instead the sentiment was more one of 'finally its happening'.
That sentiment however is more a reflection of shareholder impatience and doesn't do justice to the amazing opportunity that lies ahead.
It is likely that the trial results will be complete by the end of the month, then collated and analysed.
The hope that we get some left field announcement regarding some WHO is, I feel, unlikely and even if it occurs it is possible that it will be of such a charitable arrangement that it will be unlikely to yield a significant northward push to the SP. It has never been abundantly clear to me what the exact terms and expectation were from the Gates Foundation so I am not going to pin delusional hopes on it projecting us into the stratosphere. Maybe others have dug more deeply into this.
Prior to the FDA submission, I anticipate an announcement to the marker with the trial results. I'd be expecting June sometime. If the data had been collected efficiently, as to allow for an easy electronic collation and analysis of the data; I'd be hoping that we see something announced early June.
What is clear to me is that if/when positive trial results come out, it will place ResApp on triumphant display to the world; removing all shadow of doubt that it does indeed have a product that is both effective and poised to become an incredible money spinner.
That will get the party started.
Lastly, I agree DJ; this will run ahead of announcements.
Cheers
CT
Expand
